Valproate (VPA), one of the mood stabilizers and antiepileptic drugs, was recently found to inhibit histone deacetylases (HDAC). Increasing reports demonstrate that VPA has neurotrophic effects in diverse cell types including midbrain dopaminergic (DA) neurons. However, the origin and nature of the mediator of the neurotrophic effects are unclear. We have previously demonstrated that VPA prolongs the survival of midbrain DA neurons in lipopolysaccharide (LPS)-treated neuron-glia cultures through the inhibition of the release of pro-inflammatory factors from microglia. In this study, we report that VPA upregulates the expression of neurotrophic factors, including glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) from astrocytes and these effects may play a major role in mediating VPA-induced neurotrophic effects on DA neurons. Moreover, VPA pretreatment protects midbrain DA neurons from LPS or 1-methyl-4-phenylpyridinium (MPP þ )-induced neurotoxicity. Our study identifies astrocyte as a novel target for VPA to induce neurotrophic and neuroprotective actions in rat midbrain and shows a potential new role of cellular interactions between DA neurons and astrocytes. The neurotrophic and neuroprotective effects of VPA also suggest a utility of this drug for treating neurodegenerative disorders including Parkinson's disease. Moreover, the neurotrophic effects of VPA may contribute to the therapeutic action of this drug in treating bipolar mood disorder that involves a loss of neurons and glia in discrete brain areas. Molecular Psychiatry ( Keywords: BDNF; GDNF; valproate; astrocytes; dopaminergic neurons; neurotrophic effects Valproic acid (VPA), a short-chain fatty acid, is a drug commonly used to treat bipolar mood disorder and seizures. Although the underlying therapeutic mechanisms are unclear, a growing body of evidence suggests that VPA has neuroprotective and neurotrophic actions. Brain imaging and postmortem studies demonstrate that bipolar mood disorder involves a decrease in the volume and number of neurons and glia in discrete brain areas thought to be important for cognition and mood regulation.
Valproic acid (VPA), a short-chain fatty acid, is a drug commonly used to treat bipolar mood disorder and seizures. Although the underlying therapeutic mechanisms are unclear, a growing body of evidence suggests that VPA has neuroprotective and neurotrophic actions. Brain imaging and postmortem studies demonstrate that bipolar mood disorder involves a decrease in the volume and number of neurons and glia in discrete brain areas thought to be important for cognition and mood regulation. 1, 2 Remarkably, the reduction in brain volume in bipolar patients was found to be largely suppressed by chronic treatment with VPA. 1 In cellular models, VPA protects rat cerebral cortical neurons and cerebellar granule cells from glutamate-induced excitotoxicity, 3, 4 and apoptotic death from stress on the endoplasmic reticulum in C6 glioma cells and PC 12 cells. 5, 6 In a rat model of stroke, post-insult VPA treatment reduces ischemia-induced brain damage, caspase-3 activation and neurological deficits. 7 A number of studies reported that VPA activates cell survival factors such as Akt, 8 extracellular signalregulated protein kinase 9 and cyclic AMP response element binding protein. 10 Additionally, VPA induces cytoprotective proteins such as Bcl-2, 11 Grp78, 5 brainderived neurotrophic factor (BDNF) 12 and heat-shock protein 70. 7 Moreover, VPA promotes neurite outgrowth. 9 Recently, VPA at therapeutic levels was reported to inhibit histone deacetylase (HDAC), an enzyme that catalyzes the removal of acetyl group from lysine residues of histones. 13, 14 Thus, the capability of VPA to covalently modify histone structures through enhanced acetylation may trigger changes in the expression of distinct downstream genes.
Astrocytes are increasingly recognized to play roles in neurotransmission, synaptic plasticity, neurogenesis and secretion of neurotrophic factors. [15] [16] [17] [18] [19] [20] [21] Moreover, the role of astrocytes in pathogenesis in neurodegeneration has been investigated. 22, 23 Recent reports suggest that astrocytes can be an important target for the development of neuroprotective drugs. 24, 25 Most of the previous studies concerning the neurotrophic and neuroprotective effects of VPA emphasize its direct neuronal effects and thus might have excluded the role of glial cells, particularly astrocytes. 26, 27 The present study was undertaken to investigate the critical role of astrocytes in VPAinduced neurotrophic and neuroprotective effects and also the potential use of VPA for treating neurodegenerative disorders.
Materials and methods

Animals
Timed-pregnant Fisher F344 rats were obtained from Charles River Laboratories (Raleigh, NC, USA). Housing and breeding of the animals were performed in strict accordance with the National Institutes of Health guidelines.
Rat mesencephalic neuron-glia cultures
Neuron-glia cultures were prepared from the ventral mesencephalic tissues of embryonic day 13-14 Fisher 344 rats, as described previously. 28 In brief, dissociated cells were seeded at a density of 5 Â 10 5 /well to poly-D-lysine-coated 24-well plates. Cells were maintained at 371C in a humidified atmosphere of 5% CO 2 and 95% air, in minimal essential medium, containing 10% fetal bovine serum (FBS), 10% horse serum, 1 gm/l glucose, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 mM non-essential amino acids, 50 U/ml penicillin and 50 mg/ml streptomycin. Unless otherwise indicated, 7-day-old cultures were used for treatment. At this time, the cultures contained 11% microglia, 48% astrocyte and 41% neurons, among which about 1% of cells represent tyrosine hydroxylase-immunoractive (TH-IR) neurons, based on immunocytochemical analysis. Microglia depleted mesencephalic neuron-glia cultures were obtained by adding 1.5 mM leucine-leucine methyl ester 24 h after plating to suppress microglial proliferation. Three days later, cultures were changed back to the maintenance medium and used for treatment 7 days after initial seeding. The composition of the cells at the treatment time was about B54% astrocytes, 1% microglia and 45% neurons 29 .
Rat mesencephalic neuron-enriched cultures Dissociated ventral mesencephalic cells from embryonic day 13-14 Fisher 344 rats were seeded first at a density of 5 Â 10 5 /well to poly-D-lysine-precoated 24-well culture plates. Twenty four h after plating, cytosine-b-D-arabinofuranoside (10 mM) was added to the cultures to inhibit the proliferation of nonneuronal cells, notably glia. Three days later, the culture medium was replaced with the maintenance medium. Routinely, the 7-day-old neuron-enriched cultures, which contained less than 0.1% microglia, and 8% astrocyte, were used for treatment. Of the Neu-N immunoractive neurons, 2.7-3.9% were TH-IR neurons. 30 Rat astroglial cultures Mixed-glia cultures were first prepared from brains of 1-day-old Fisher 344 rat pups, as described previously. 28 Briefly, mechanically dissociated brain cells (5 Â 10 7 ) were seeded onto 150-cm 2 culture flasks in Dulbecco's modified Eagle's medium containing 10% heat-inactivated FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 mM non-essential amino acids, 50 U/ml penicillin and 50 mg/ml streptomycin. The cultures were maintained at 371C in a humidified atmosphere of 5% CO 2 and 95% air, and medium was replenished 4 days after the initial seeding. Upon reaching confluence (usually 12-14 days later), microglia were detached from astrocytes by shaking the flasks at a speed of 180 r.p.m. for 5 h. Astrocytes were then detached with trypsin-ethylenediaminetetraacetic acid (EDTA) and seeded in the same culture medium. After five or more consecutive passages, cells were seeded onto 24-well plates (10 5 /well) for experiments. Immunocytochemical staining of the astroglial cultures with either anti-glial fibrillary acidic protein or anti-OX-42 antibody indicated an astrocyte purity of greater than 98% and less than 2% of microglia contamination. Quantitative RT-PCR analysis Total RNA was extracted from cells by TRIzol reagent (Sigma-Aldrich, St Louis, MO, USA) and purified with RNeasy columns (Qiagen, Valencia, CA, USA). Expression of the selected genes was quantified using real-time reverse transcription polymerase chain reaction (RT-PCR) analysis. Briefly, total RNA was reverse transcribed with Moloney-murine leukemia virus reverse transcriptase and oligo-dT primers. The forward and reverse primers for glial cell line-derived neurotrophic factor (GDNF) genes were 5 0 -GAGA GAGGAACCGGCAAGCT and 5 0 -GTTAAGACGCACC CCCGATT. The forward and reverse primers for BDNF genes were 5 0 -CCATAAGGACGCGGACTTGT and 5 0 -GAGGCTCCAAAGGCACTTGA. The SYBR green DNA PCR kit (Applied Biosystems, Foster City, CA, USA) was used for real-time PCR analysis. The relative differences in expression between groups were expressed using cycle time (C t ) values and the relative differences between groups were expressed as relative increases setting the control as 100%. Assuming that the C t value is reflective of the initial starting copy and that there is 100% efficacy, a difference of one cycle is equivalent to a twofold difference in the starting copy.
DA uptake assay
GDNF ELISA GDNF levels were measured with an enzyme-linked immunosorbent assay (ELISA) kit (GDNF Emax ImmunoAssay System; Promega, Madison, WI, USA), according to the manufactures protocol of the supplier. The levels of GDNF were expressed as picogram per ml of the supernatant. The assay sensitivity ranged from 16 to 1000 pg/ml.
GDNF antibody neutralization
Neutralization of GDNF was performed by the addition of 2 mg/ml goat total anti-GDNF immunoglobulin (Ig)G (1:100 dilution; R&D Systems, Minneapolis, MN, USA) to the conditioned medium. After overnight neutralization, the conditioned medium was added to rat mesencephalic neuron-enriched cultures. [ 3 H]DA uptake assays were performed 7 days later to determine the degeneration of DA neurons.
Statistics
All statistical analyses were performed with SPSS software vs 10.0, and P-values of p0.05 were considered significant in all tests. GDNF transcript abundance was expressed as a ratio of actin internal control. For multiple comparisons of groups, analysis of variance (ANOVA) was used with treatments as the independent variable, followed by Dunnett's test. In Figure 4b , the statistical significance between groups was assessed by Student's t-test.
Results
Survival-promoting effects of VPA against spontaneous DA neuronal death [ 3 H]DA uptake assay and immunohistochemical analysis for TH-IR neurons were used to assess the viability of DA neurons in rat primary mesencephalic neuron-glia cultures in which approximately 1% of the neurons are DA. Various concentrations of VPA (0.05-1.2 mM) were added 7 days after the initial seeding and the viability of DA neurons was assessed by DA uptake assays 7 days after VPA addition. Results indicated that VPA induced survival-promoting effects in a dose-dependent manner. At 0.6 mM and 1.2 mM, VPA significantly protected DA neurons from spontaneous neuronal death (Figure 1a) . To assess the role of microglia in the VPA-induced survival-promoting effects in this in vitro system, microglia-depleted rat primary mesencephalic neuron-glia cultures were treated with 0.3, 0.6 or 1.2 mM VPA and DA uptake assays were performed 7 days after VPA treatmet (Figure 1b) . Figure 1 showed no significant difference in the capacity of DA uptake in microglia-depleted ( Figure  1b ) and non-depleted mesencephalic neuron-glia cultures (Figure 1a) . These results indicate that microglia play a negligible role in VPA-induced survival-promoting effects.
Next, a time course study was performed by treating the rat primary mesencephalic neuron-glia cultures with 0.6 mM VPA for 1-7 days. VPA treatment increased the capacity of [ (Figure 2a and b) . In the DA-uptake study (Figure 2a) , the steady increases in the uptake capacity after day 3 in both vehicle-and VPA-treated groups were likely owing to the increases in neurite growth with time. The more pronounced increase in DA uptake in VPA-treated cultures than control group might be attributed to the neurotrophic effects on survival of TH neurons and enhanced neurite growth; resulting from the release of neurotrophic factors from astrocytes by VPA (see Figure 3 ). In the cell count study, there was a steady decline of the number of TH-IR neurons in the vehicle-treated control group, whereas, the TH-IR neuronal numbers remained relatively constant in the VPA-treated group ( Figure  2b ). These results suggest that VPA enhanced the survival of TH-IR neurons.
Roles of astrocytes in VPA-induced neurotrophic effects To explore whether astrocytes are involved in the VPA-induced survival-promoting effects, we prepared media conditioned by incubation of astroglial cultures in the absence or presence 0.6 mM VPA. The astrocyte-conditioned medium (ACM) derived from incubation with astrocytes for 12, 24 or 48 h showed an approximate four-fold increase in DA uptake following incubation of mesencephalic neuron-enriched cultures with ACM for 7 days ( Figure 3A) . The conditioned medium derived from 48 h incubation of astrocytes in the presence of 0.6 mM VPA (ACM-VPA) displayed a more robust (more than eight-fold), timedependent increase in DA uptake. Exposure of the neuron-enriched cultures to 0.6 mM VPA for 7 days caused a less than two-fold increase in DA uptake, suggesting that a direct neuronal effect of VPA does not play a major role in VPA-induced neurotrophic effects. To exclude the possibility that the effects of ACM-VPA were owing to the presence of VPA in the conditioned medium, 48 h ACM-VPA and ACM were dialyzed overnight using the Slide-A-Lyzer Dialysis Cassette (Pierre Biotechnology Inc., Rockford, IL, USA). Dialyzed ACM-VPA displayed a 155% increase in DA uptake, compared with dialyzed ACM. Thus, the dialyzed ACM-VPA still retained its ability to enhance DA uptake.
Morphological examination of neuron-enriched cultures immunostained with mitogen-activated protein (MAP)-2 demonstrated a dramatic increase in neurite outgrowth following exposure for 7 days to ACM-VPA conditioned with 48 h VPA incubation with astrocytes ( Figure 3B-d) , compared with the vehicle-treated control cultures ( Figure 3B-a) . Much smaller effects were observed following incubation with the VPA alone or corresponding ACM ( Figure  3B-b, c) . Next, we immunostained neuron-enriched cultures with anti-TH antibody to specifically visualize morphological changes in DA neurons. Results demonstrated a higher density of DA neurons, more complex neurite configurations and more neuronal Figure 3C-a) . Cell count analysis indicates that the numbers of TH-IR neurons in cultures treated with ACM-VPA, ACM and VPA were 422, 276 and 111%, respectively, of that in vehicle-treated cultures. The increases in the number of TH-IR neurons are proportional, but less in magnitudes, to the increases in [ 3 H]DA uptake ( Figure  3A) . These results indicate that ACM-VPA-treated conditioned media not only increased the number of TH-IR neurons, but also enhanced the neurite growth, which explains the larger increases in the capacity of [ VPA upregulate GDNF and BDNF expression in astrocytes GDNF has been shown to promote DA neurons survival, induce neurite outgrowth and sprouting, [31] [32] [33] upregulate TH expression and enhance synaptic efficacy. 34 The presence of GDNF messenger RNA (mRNA) in the astrocytes of substantia nigra, 35, 36 and the high sensitivity of DA neurons to this neurotrophin make GDNF a likely candidate for the yet unidentified VPA-induced, astrocytes-secreted neurotrophic substance. [37] [38] [39] To test this possibility, we used real-time PCR to quantify GDNF mRNA. Results showed that VPA treatment caused a time-dependent increase in GDNF mRNA levels in astroglial cultures. This increase was about 180% at 12 h, 265% at 24 h, 160% at 36 h and back to the control value at 48 h ( Figure 4a) . Next, the quantity of secreted GDNF protein from ACM treated with VPA for 48 h was analyzed by ELISA. ACM-VPA showed a 2.1-fold increase over the vehicle control in levels of GDNF protein (39 vs 83 pg/ml) (Figure 4b ). To investigate whether GDNF-neutralization interfered with the VPA-induced effects on DA neurons, ACM-VPA was pretreated with goat anti-GDNF IgG overnight before the addition to mesencephalic neuron-enriched cultures. The GDNF-neutralizing antibody significantly reduced the ACM-VPA-induced increase in DA uptake capacity following 7 days of incubation, whereas pretreatment with control IgG was without effect (Figure 4c) .
Because anti-GDNF antibody only partially attenuates the neurotrophic effects of ACM-VPA, it is possible that concerted actions of GDNF with other VPA-induced neurotrophic substances are necessary to fully promote the survival and growth of DA neurons. 40 It is noted that BDNF is induced in the brain of rats chronically treated with VPA. 12 An in vivo study also showed that the loss of DA neurons with double mutants of BDNF and GDNF is nonadditive, compared with BDNF or GDNF single null mutant. 41 We then used real-time PCR to quantify the expression of BDNF in astrocytes after VPA treatment. Results showed that VPA treatment also caused a time-dependent increase in BDNF mRNA levels. This increase was about 210% at 12 h, 300% at 24 h and 320% at 48 h (Figure 4d ). 
VPA robustly protects DA neurons from neurotoxicity induced by LPS and MPP þ
To investigate the potential use of VPA for treating neurodegenerative disorders, we tested the neuroprotective effects of VPA in the primary mesencephalic neuron-glia cultures stimulated with lipopolysaccharide (LPS) that produced specific DA neuronal degeneration. 42 Cultures were pretreated with various doses of VPA for 48 h and then expose to 10 ng/ml LPS for 5 days. LPS treatment reduced the uptake capacity of DA by 45% and this reduction was robustly blocked by VPA pretreatment in a dosedependent manner ( Figure 5A ). In fact, at 0.6 mM with 48 h-pretreatment, the DA uptake levels in the VPApretreated cultures, either alone or in conjunction with LPS, were significantly higher than those in the vehicle-treated cultures. Similar results were obtained by counting the number of TH-IR neurons after immunostaining. The number of TH-IR neurons in cultures 48 h-pretreated with 0.6 mM VPA in conjunction with LPS was 237% of that in LPStreated cultures. The neuroprotective effects of VPA were dependent on the time of pretreatment. Although pretreatment with 0.6 mM VPA for 6 h failed to induce a significant effect, a 12 h-pretreatment produced a complete neuroprotection against LPS neurotoxicity and a 48 h-pretreatment caused a further increase in DA uptake levels ( Figure 5B ). Morphological assessments of DA neurons immunostained with anti-TH antibody revealed that VPA treatment promoted neurite formation and interneuronal networks ( Figure 5C-a, b) . In contrast, LPS treatment caused degeneration of DA neuronal soma and loss of neurites and dendritic nodes ( Figure 5C-c) . These LPS-induced morphological changes were dose dependently prevented by VPA pretreatment in the concentration range examined (0.2-0.6 mM) ( Figure 5C-d-f) . Finally, we investigated whether VPA could also protect against neurotoxicity induced by 1-methyl-4-phenylpyridinium (MPP þ ), a widely used toxin in a rodent Parkinson's disease (PD) model, in the rat primary mesencephalic neuron-glia cultures. 43 Treatment with 0.5 mM MPP þ for 7 days resulted in a decrease by more than 70% in DA uptake levels ( Figure 6 ). Treatment with 0.6 mM or 1.2 mM VPA significantly reduced the MPP þ -induced degeneration of DA neurons. Although pretreatment with 0.3 mM VPA failed to show the neuroprotective effect, 0.6 mM VPA produced a complete neuroprotection against MPP þ -induced neurotoxicity and 1.2 mM VPA caused a further increase in DA uptake levels ( Figure 6 ).
Discussion
To our knowledge, the present study is the first to demonstrate that VPA upregulates BDNF and GDNF expression in the astrocytes which play a prominent role in mediating the VPA-induced neurotrophic effects on mesencephalic DA neurons. The dependence of astrocytes in expressing the neurotrophic effect of VPA on DA neurons is evident from the result showing that VPA increases DA uptake by merely 20% in neuron-enriched cultures with very little astroglia present ( Figure 3A ), compared to more than 200% increase in neuron/glia cultures (Figure 1) .
Although a number of studies demonstrate that VPA activates neuronal-survival signaling pathways and increase BDNF levels in vivo, 8, 9 our results lend support of the view these effects might be initiated by VPA-induced release of neurotrophic factors from astrocytes. Recent in vivo studies have shown that treatment with HDAC inhibitors of a wide range of structures provide neuroprotective effects in models of various motor neuron disorders. [44] [45] [46] [47] However, the roles of glia under therapeutic mechanisms of HDAC inhibitors were not investigated. Here we showed that the neurotrophic effects of VPA, a HDAC inhibitor of short-chain fatty acid structure, were associated with Figure 5 VPA is neuroprotective against LPS-induced DA neurodegeneration in rat primary mesencephalic neuronglia cultures. (A) Dose-dependent effects of VPA on LPSinduced DA neuron degeneration. The cultures seeded in a 24-well plate were treated for 48 h with indicated concentrations of VPA followed by treatment with 10 ng/ml LPS for 7 days. (B) Time-dependent neuroprotective effects of VPA on LPS-induced DA neuron degeneration. The cultures seeded in a 24-well plate were treated for indicated time with 0.6 mM VPA followed by treatment with 10 ng/ml LPS for 7 days. Results are expressed as mean7s.e.m. of percentage of vehicle-treated control cultures from three independent experiments performed in duplicate. The differences were analyzed using a multifactor ANOVA followed by Dunnett's test. *P < 0.05 compared with vehicle-treated control cultures. regulation of neurotrophic factors in astrocytes. Oneway VPA induces GDNF and BDNF expression in the astrocytes is through alternations in histone modifications and/or transcription factors. Our preliminary results showed that sodium butyrate and trichostatin A, two other structurally dissimilar HDAC inhibitors produced similar neurotrophic effects (Wu et al., unpublished data). It is likely that GDNF released from astrocytes are among the components in the ACM-VPA that mediate the neurotrophic/neuroprotective effects in the midbrain DA neurons shown in this study. GDNF application has been shown to prevent and reverse sensory abnormalities in neuropathic pain that can be suppressed by VPA treatment. 48 GDNF supplement has also been considered as a potential therapy for neurodegenerative diseases related to neurotrophic factor deficiency. 49 Till now, clinical investigations have been hampered by the lack of an adequate, efficient delivery method of GDNF into the target brain areas, and complicated by the invasive procedures and adverse side effects. 50, 51 Therefore, the search for a compound like VPA whereby endogenous GDNF can be upregulated seems warranted.
In this study the neuroprotective effects of VPA were studied with in vitro rodent PD models with two neurotoxins with different mode of actions, LPS and MPP þ . MPP þ is known to cause DA neurotoxicity by directly acting on mitochondrial complex I. In contrast, LPS exerts neurodegeneration by activating microglia to release a variety of pro-inflammatory factors to impact neurons. 42 We have previously reported that LPS in the concentrations used did not cause any damage of astrocytes. 52 Previous report from our laboratory also demonstrated that VPA suppresses microglial activation and downregulate pro-inflammatory factors expression in midbrain primary cultures stimulated with LPS. 53 The suppression of neuroinflammation by VPA coupled with the release of astrocytic trophic factors reported in this study make the combined actions of VPA highly effective for therapeutic intervention in PD and possibly other neurodegenerative diseases.
The mechanisms underlying the differential effects of VPA on astrocytes and microglia are under investigation in our laboratory. Inhibition of HDAC activity was reported to be associated with neuroprotective effects in experimental models of motor neuron disorders by HDAC inhibitors with different chemical structures. [44] [45] [46] [47] Preliminary results from our laboratory suggests that inhibition of HDAC in astroglial cultures is related to the increase in the expression of GDNF and BDNF by VPA treatment (Wu et al., personal communication) .
The decreased release of neurotrophic factors from astrocytes might play a role in the loss of cellular resilience and the decrease in brain volume observed in patients with bipolar mood disorder. Previous reports show regional brain volume reductions in bipolar patients. 1, 54, 55 Moreover, chronic treatment with VPA attenuates the brain atrophy process. 56 Additionally, a number of molecules involved in neurotrophic signaling cascades are long-term targets for VPA. 57 This suggests that neurotrophic and neuroprotective effects of VPA plays a critical role in the therapeutic effect of bipolar disorder. 58 Furthermore, newer antiepileptics that share the same action of VPA to inhibit HDAC are clinically effective in treating bipolar mood disorder. 59 Further understanding the mechanism underlying the neurotrophic acton of VPA will provide an avenue to disclose both the pathogenesis and therapeutic mechanisms underlying bipolar mood disorder. 2, 60, 61 The results of our study underline the emerging role of glia as active participants in neuronal survival and plasticity, with astrocytes being strongly implicated as the major player in these responses. It reinforces the view that disturbances of astroglial function could conceivably contribute to pathogenesis of various forms of brain disorders and that astrocytes may serve as an appropriate target for the development of novel therapeutics. Understanding the interplays among neurons and different glial cells may help further illuminate the pathophysiology underlying complex neurodegenerative and psychiatric disorders.
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